Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biopharma company Regeneron Pharmaceuticals
So what: Positive study data is pretty much always music to the ears of biopharma investors. In Regeneron's case, the company -- along with partner sanofi-aventis
Now what: Commenting on the results, Regeneron's chief scientific officer said that Regeneron and sanofi-aventis will now submit applications for marketing approval for Zaltrap to the U.S. Food and Drug Administration and the European Medicines Agency in the second half of the year. Investors in sanofi-aventis hardly blinked at the news, as the market for Zaltrap is relatively modest. However, for a smaller company like Regeneron, the impact of an approval (which is still far from guaranteed) would be more significant.
Want to keep up to date on these stocks?
Fool contributor Matt Koppenheffer does not have a financial interest in any of the companies mentioned. You can check out what Matt is keeping an eye on by visiting his CAPS portfolio, or you can follow Matt on Twitter @KoppTheFool or on his RSS feed. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool’s disclosure policy prefers dividends over a sharp stick in the eye.